Heat Shock Proteins Flashcards

1
Q

BRAIN AMYLOIDOSES

A

Protein aggregates with typical amyloid structure are common among many different neurodegenerative disorders, collectively defined BRAIN AMYLOIDOSES (AD, PD, ALS, HD, polyQ diseases, etc)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

Amyloid structure & toxicity

A

A common feature of all forms of amyloid aggregates is the initial acquisition of a b-sheet secondary structure that may be responsible for shared mechanisms of toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

Structure of amyloid aggregates over time

A

Natively unfolded can go into protofibril –> fibril or toxic pore
Or natively unfolded proteins can form alternative conformations (with increased/decreased toxicity depending on additional factors)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Fibrillary structures

A

Fibrillary structures often display the properties of amyloid (~10 nm-wide fibrils
with crossed B-pleated sheet structures)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

Toxic pore structure

A

pores insert into membrane –> leakage of material causing toxicity

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

Ideal protein folding and what dictates it

A

Primary structure (aa’s) dictate protein folding and favours the most energetically/thermodynamically stable conformation

BUT cellular enviro/crowding can alter this folding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

How the cellular enviro can alter folding

A
  • the cytosol is packed with proteins and this enviro can lead partially folding proteins to misfold leading to misfolding and aggregation
  • but chaperones can help direct proteins into certain conformations
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

T/F only partially folded/unfolded proteins risk misfolding

A

FALSE

even proteins that are already folded risk unfolding–esp when under cellular stress

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

Chaperone–roles

A
  • can help with refolding or may push proteins to wither a disordered aggreagtes or amyloid fibrils
  • can also help deliver misfolded proteins for degradation (proteasomal or autophagy)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

Chaperone–role brief

A

refolding AND removal of misfolded proteins (proteostasis)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Molecular chaperones

A

enhance the efficiency of de novo protein

folding and promote the refolding of misfolded proteins

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

Chaperones in healthy cells

A

In healthy cells, misfolded proteins are refolded correctly through the intervention of molecular chaperones or are degraded by the proteosomal system or by autophagy

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

Chaperones as we age

A

With aging, the induction and/or activity of molecular chaperones and the function of the proteosomal system decrease, favoring accumulation of toxic misfolded proteins (impaired proteostasis).
This may account for the late onset of neurodegenerative diseases that are linked to protein aggregation.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

Molecular chaperones have roles in

A
  • proteosomal degradation
  • macroautophagy
  • non-conventional secretion
    = removal of misfolded proteins to decrease toxic burden

And folding and refolding

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Monomers misfolding

A

While acquiring a misfolded conformation is often thermodynamically favourable the conversion back may require more energy to occur
- molecular chaperones can intervene and help return the protein to its native conformation

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Molecular chaperones and direction of monomer folding

A

by stabilizing a native or misfolded monomeric conformation chaperones, incl. HSP 40/70, might prevent the intramolecular transition that gives rise to spherical and annular oligomers WHILE simultaneously stabilizing those that lead to inclusion body formation (amorphous aggregates and fibrils) –> likely less toxic

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
17
Q

heat shock protein HSP) families

A

Five main families of ATP-binding, heat shock proteins (HSP):
HSP100, HSP90, HSP70, HSP40 and small HSPs (sHSPs)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

HSP90

A

Cytosolic dimeric chaperone that stabilizes misfolded proteins and regulates the activity of various signalling proteins:

  • steroid hormone receptors
  • tyrosine kinases
  • nitric oxide synthase
  • calcineurin, etc.
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

HSP70

A

assists in the stabilization and folding of many substrates and is found in most cellular compartments.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

HSP40

A

co-chaperones that bind misfolded proteins and target them to HSP70.
In complex with HSP70, HSP40 proteins stimulate ATP hydrolysis, resulting in a conformational switch that facilitates the folding of non-native protein substrates.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
21
Q

HSP40 and 70

A

misfolded proteins first bind to HSP40 then are delivered to HSP70
binding of ATP to HSP40 and subsequent ATP hydrolysis causes a conformational change allowing refolding of the non-native protein substrate

22
Q

HSP90 Cycle process (6 steps)

A

1) Hop binds to HSP90 dimer
2) Hop recruits ‘Hsp40/70-client complex’
3) ATP binds to HSP90 + changes HSP90 conformation to ‘closed’
4) p23 binds HSP90 in ‘closed’ confirmation and promates client protein activation (i.e. changes folding of client)
5) activated client released with ATP hydrolysis
6) ADP released and HSP90 reverts to ‘open’ conformation

23
Q

How does a protein get refolded vs degradated

A

Depending on associated proteins and chaperones the proteins that bind (i.e. the client) can either be:

  • stabilized and refolded
  • directed to proteosomal degradation
24
Q

HSF 1

A

Transcriptional activator that controls the cellular response to cytoplasmic proteotoxic stimuli (elevated temperature, oxidative stress, viral infections etc.)

HSF1 controls the expression of chaperone proteins in response to cellular stress.

25
Q

HSF-1 response is ____ due to

A

Transient; negative feedback from HSP40/70
- Even under conditions of chronic proteotoxic stress, HSF1-dependent transcription of chaperone proteins is transient, because HSF1 is negatively regulated via a feedback loop by HSP70 and HSP40 binding

26
Q

HSF-1 under normal conditions

A

some extra HSP40/70/90 is present in the cytosol as inactive complex with HSF-1
- always some HSPs that are actively folding BUT excess is sequestered into these complexes

27
Q

HSF-1 in cellular stress conditions

A

When exposed to stress/increased conc of misfolded proteins need more HSPs to deal
–> HSPs are removed from complex with HSF-1 –> HSPs go help fold, HSF-1 trimerziess and enters the nucleus –> increased transcription of HSP genes –> more HSP40/70 etc. to help cope with stress

28
Q

Negative feedback of HSF-1

A

Following increased transcription of HSP genes and increased HSP production –> elevated cytosolic HSPs will lead to the reformation of inactive complexes with HSF-1 leading to negative feedback onto HSP40/70/90

29
Q

HSPs in neurodegeneration: AD

A
  • HSP70 overexpression decreases aggregation of hyperphosphorylated tau in tangles
  • Inhibition of HSP70 expression has the opposite effect
30
Q

HSPs in neurodegeneration: PD

A

HSP70 promotes degradation of α-synuclein

31
Q

HSPs in neurodegeneration: ALS

A

HSP70 decreases toxicity of mutant SOD1

32
Q

HSPs in neurodegeneration: HD

A

Overexpression of HSP40 and HSP70 in HD models decreases mutant Htt toxicity.

33
Q

HSPs in neurodegeneration: other HSPs

A

HSPs other than HSP40/70 have shown protective effects in a variety of
protein-misfolding diseases

34
Q

Geldanamycin: what is it

A
  • Geldanamycin (GM) is a natural product
    originally developed as antifungal agent.
  • an anticancer drug with neuroprotective action
  • Initial studies demonstrated antitumor
    effects of GM, but liver toxicity
35
Q

17-AAG

A

a compound with similar biological
activity to Geldanamycin, but decreased toxicity
GM analogue w/o the toxicity

36
Q

Geldanamycin/17-AAG: mechanism

A

inserts into the ATP binding pocket of HSP90 –> blocks the HSP90 cycle –> leads to proteosomal degradation of client protein
= anti-tumoral if client was a cancer-protein
= anti-NDD if the client was mutant tau etc.

37
Q

Why inhibit HSP90: stabilized proteins

A
  • HSP-90 is involved in stabilization of many misfolded protein conformations incl. tau, alpha-syn, PINK1 –> promotes disease progression in NDDS
  • therefore blocking HSP90 blocks stabilization of these and promotes their degradation –> decreases cellular stress
38
Q

Why inhibit HSP90: chaperone production

A

inhibition of HSP-90 results in the release of HSF-1 from the complex with inactive chaperones (likely due to increased recruitment of these chaperones following HSP90 inhibition)
once released HSF1 trimerizes, enters the nucleus and increases chaperone transcription

39
Q

Benefits of inhibiting HSP90

A
  • prevent stabilization of pathological clients and therefore promote their degradation
  • activation of HSF1 and the production of more chaperones (which promotes proper folding, refolding or degradation of pathological protein conformations)
40
Q

Geldanamycin in transgenic flies

A

Geldanamycin treatment prevents dopaminergic cell loss in α-synuclein transgenic flies
due to upregulation of HSP70

41
Q

Clinical use of HSP90 inhibitors: 17AAG

A

17-AAG and other synthetic inhibitors of HSP90 are in clinical trials (Phase I/II) for the treatment of various types of cancers.

No clinical trials in neurodegenerative conditions

42
Q

Barriers to 17-AAG use in NDDS

A
  • 17-AAG is a substrate of P-glycoprotein and its passage through the BBB might be a problem (can’t accumulate in the brain –> not effective for neurological treatments)
  • Also shows some liver toxicity, but not with the use of synthetic inhibitors
43
Q

SNX-0723: what is it

A
  • a synthetic inhibitor of HSP90
  • a benzamide derivative and its
    analogues are a novel class of synthetic small molecule HSP90 inhibitors that emerged from the screening of compounds that selectively bind to the ATP pocket of HSP90
44
Q

Synthetic inhibitors of HSP90

A

13 are in clinical trials for cancer

treatment

45
Q

SNX-0723: in PD

A
  • SNX0723 increases HSP70 levels and decreases alpha-synuclein oligomerization and toxicity in vitro
46
Q

SNX-0723 vs. 17-AAG

A
  • SNX-0723 is more potent than 17-AAG

- can cross the BBB (unlike 17AAG) and therefore is a potential drug candidate for PD

47
Q

Drugs that increas HSF1 activity

A

17AAG, SNX-0723
Riluzole
NSAIDs
Arimoclomol

48
Q

Riluzole

A

Increases the steady-state levels of HSF1, by inhibiting its degradation.

Riluzole is better known as glutamate modulator (see lecture on excitotoxicity).

49
Q

NSAIDs

A

High concentrations of non-steroidal anti-inflammatory drugs such as sodium salicylate and indomethacin synergize with
cellular stress and increase binding of HSF1 to DNA during cellular stress.

50
Q

Arimoclomol (BRX-220)

A
  • Hydroxylamine derivative that prolongs
    stress-induced activation of HSF1 by binding to the active form of HSF1 and stabilizing it.
  • acts as a “smart drug” as it acts increasing the heat shock response only in cells that are already under stress.
51
Q

Arimoclomol: clinical uses

A

Arimoclomol is in Phase III clinical trial in patients with SOD1-positive ALS.
SOD1 + placebo = decreased motor neurons
SOD1 + Arimoclomol = increased motor neurons, mice survived longer